SAM
Sherman Asset Management Portfolio holdings
AUM
$113M
This Quarter Return
+1.8%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$109M
AUM Growth
–
Cap. Flow
+$109M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
60.84%
Holding
177
New
176
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
iShares Core S&P 500 ETF
IVV
|
$19.6M |
| 2 |
Vanguard Total Stock Market ETF
VTI
|
$10.1M |
| 3 |
iShares Core S&P Small-Cap ETF
IJR
|
$8.51M |
| 4 |
Technology Select Sector SPDR Fund
XLK
|
$7M |
| 5 |
Eli Lilly
LLY
|
$4.64M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 9.01% |
| 2 | Communication Services | 7.02% |
| 3 | Healthcare | 5.96% |
| 4 | Consumer Discretionary | 4.21% |
| 5 | Consumer Staples | 2.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Vanguard Growth ETF
VUG
$185B
| $16.8K | 0.02% |
+41
| New | +$16.8K |
|
127
3M
MMM
$81B
| $14.3K | 0.01% |
+111
| New | +$14.3K |
|
128
CVS Health
CVS
$93B
| $12.7K | 0.01% |
+283
| New | +$12.7K |
|
129
Tyson Foods
TSN
$20B
| $10.1K | 0.01% |
+175
| New | +$10.1K |
|
130
Booking.com
BKNG
$181B
| $9.94K | 0.01% |
+2
| New | +$9.94K |
|
|
ITCI
131
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.19K | 0.01% |
+110
| New | +$9.19K |
|
132
TJX Companies
TJX
$155B
| $8.7K | 0.01% |
+72
| New | +$8.7K |
|
133
Whirlpool
WHR
$5B
| $8.27K | 0.01% |
+72
| New | +$8.27K |
|
134
Lowe's Companies
LOW
$146B
| $7.9K | 0.01% |
+32
| New | +$7.9K |
|
135
Hormel Foods
HRL
$13.9B
| $7.62K | 0.01% |
+243
| New | +$7.62K |
|
136
Cytokinetics
CYTK
$5.98B
| $6.68K | 0.01% |
+142
| New | +$6.68K |
|
137
Mondelez International
MDLZ
$79.3B
| $6.15K | 0.01% |
+103
| New | +$6.15K |
|
138
Spotify
SPOT
$143B
| $5.82K | 0.01% |
+13
| New | +$5.82K |
|
139
ASML
ASML
$290B
| $5.55K | 0.01% |
+8
| New | +$5.55K |
|
140
Alnylam Pharmaceuticals
ALNY
$58.6B
| $3.53K | ﹤0.01% |
+15
| New | +$3.53K |
|
141
Trupanion
TRUP
$1.9B
| $3.09K | ﹤0.01% |
+64
| New | +$3.09K |
|
142
Avantor
AVTR
$8.74B
| $2.78K | ﹤0.01% |
+132
| New | +$2.78K |
|
143
Sea Limited
SE
$107B
| $2.76K | ﹤0.01% |
+26
| New | +$2.76K |
|
144
DexCom
DXCM
$30.9B
| $2.18K | ﹤0.01% |
+28
| New | +$2.18K |
|
145
Apellis Pharmaceuticals
APLS
$3.51B
| $2.01K | ﹤0.01% |
+63
| New | +$2.01K |
|
146
Denali Therapeutics
DNLI
$2.24B
| $1.92K | ﹤0.01% |
+94
| New | +$1.92K |
|
147
Solventum
SOLV
$12.4B
| $1.78K | ﹤0.01% |
+27
| New | +$1.78K |
|
148
AnaptysBio
ANAB
$630M
| $1.59K | ﹤0.01% |
+120
| New | +$1.59K |
|
149
Bank of New York Mellon
BK
$73.8B
| $1.38K | ﹤0.01% |
+18
| New | +$1.38K |
|
150
T-Mobile US
TMUS
$284B
| $1.32K | ﹤0.01% |
+6
| New | +$1.32K |
|